INS and metabolic dysfunction-associated steatohepatitis: With the improved understanding of the multifactorial pathophysiology of MASH, approaches to treating it have continued to diversify, targeting a variety of disease processes, including metabolic regulatory and insulin-sensitizing effects to direct antifibrotic activity.